Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, phase III study to evaluate the efficacy of rituximab maintenance
therapy in patients aged between 18 and 65 years inclusive undergoing first-line treatment
for mantle cell lymphoma and exhibiting a response after autologous transplantation.